MRTX News and Press, Mirati Therapeutics Inc. From 10/02/19

The European Society for Medical Oncology (ESMO) meeting, which wrapped up on Tuesday, featured presentations from a few smaller companies that saw their stock prices move substantially after the meeting. Data source: YCharts. Seattle Genetics wowed investors with a pair of clinical trials. ...

Amgen (NASDAQ: AMGN ) moves  down 2.0%  in premarket trading after disclosing new data from the ongoing early-stage study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. More news on: Amgen Inc., Mirati Therapeutics, Inc., Stocks on the mov...

Adamas Pharmaceuticals (NASDAQ: ADMS ) initiated with Neutral rating and $8 (50% upside) price target at Cantor Fitzgerald. More news on: Adamas Pharmaceuticals, Inc., Covetrus, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...

Amgen (NASDAQ: AMGN ) is down  4%  premarket on light volume after announcing updated data from a Phase 1 clinical trial evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. The results were presented at the World Conference on Lung Cancer in Bar...

The biopharmaceutical industry has been exploding, with roughly one new initial public offering every week. There are so many drug developers out there, new and old, that it can be tough to spot the ones about to soar or crash. You could try watching the sky for a shooting star, but that really...

Shares of Mirati Therapeutics ( MRTX ) have risen by 630% since my September 2017 article stated that a double on early data for sitravatinib could be just the beginning. On the other hand, the stock has fallen by 17% since my June update piece detailed how the company "won" at ASCO withou...

SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced the appointment of Jenny Gizzi as Vice President, Human Resources, reporting directly to Charles M. Baum, M.D., Ph.D., President and Chief ...

Mirati Therapeutics Inc. ( MRTX ) stock has seen quite some interest in recent times, especially after Amgen (AMGN) reported preclinical data from the study of their KRAS G12C inhibitor drug AMG 510. However, this is not its lead candidate, and we don't gauge companies by looking at molecules ...

Mirati Therapeutics (NASDAQ: MRTX ): Q2 GAAP EPS of -$1.26. More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019 . Second Quarter Highlights: Initiated the Phase 3 randomized clinical trial, ...